8 min read | February 2026 HD research recap: published trial data from branaplam trial; new insights into the genetics of the HD “grey zone”; plus worms, brain circuits, eye tracking, and the hidden ...

A new review from the University of Cambridge explores ocular biomarkers in HD, including retinal scans and eye movement tracking.

The most complex computer in the world is not made of microchips – it’s sitting right inside your head. Although the fastest supercomputers rival the human brain for raw computational power, nothing ...

At other times, stepping into the non-HD world allowed them to rest, recover, and reconnect with who they were, beyond the ...

The results of a clinical trial, called VIBRANT-HD, investigating an oral drug designed to lower huntingtin (HTT) protein have now been published in Nature Medicine. This study found that the drug ...

For individuals in the HD “grey zone” between 36-39 repeats, an understanding of when symptoms may arise and what kind of symptoms is critical. A new study sheds light on different sequence patterns ...

If you’ve tried to follow Huntington’s disease (HD) clinical trials recently, you’ll know the feeling: so many trials, so many acronyms, and so many announcements. It’s a fantastic problem to have!

On December 4, 2025, uniQure announced they have received the final meeting minutes from their October 29 pre-Biologics License Application (BLA) meeting with the FDA regarding AMT-130. The minutes ...

When it comes to thinking about the effects of Huntington’s disease (HD), most people automatically start to think about the brain due to the severe symptoms caused by the breakdown of brain cells. It ...

SOM3355 is an investigational therapy aimed at managing multiple symptoms of Huntington’s disease (HD) and recently crossed two key regulatory milestones. In September, the European Medicines Agency ...

Scientists often use genetics, the study of DNA, to understand the cellular changes that cause disease. By comparing people’s DNA with their symptoms, they can pinpoint specific genetic differences, ...

Why do some people with intermediate CAG repeats, a genetic “gray zone” in Huntington’s disease, develop neurological symptoms while others do not? This article covers a recent study that tackled this ...